The prevalence of chronic airflow obstruction in three cities in the Nordic-Baltic region.
To access publisher's full text version of this article click on the hyperlink below Chronic airflow obstruction (CAO) is the primary characteristic of Chronic obstructive pulmonary disease (COPD) but is also seen in chronic asthma. To compare the prevalence of CAO and possible risk factors bet...
Published in: | Respiratory Medicine |
---|---|
Main Authors: | , , , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
W.B. Saunders
2018
|
Subjects: | |
Online Access: | http://hdl.handle.net/2336/620730 https://doi.org/10.1016/j.rmed.2018.08.007 |
Summary: | To access publisher's full text version of this article click on the hyperlink below Chronic airflow obstruction (CAO) is the primary characteristic of Chronic obstructive pulmonary disease (COPD) but is also seen in chronic asthma. To compare the prevalence of CAO and possible risk factors between Tartu in Estonia, Reykjavik in Iceland and Uppsala in Sweden. All participants underwent spirometry testing of forced expiratory volume in 1 s (FEV 1037 men and 956 women participated in the study. The prevalence of CAO was lower in women in Tartu compared to the other centres (4.9% vs. 13.4 and 8.7% in Reykjavik and Uppsala, respectively, p = 0.002) while no difference was found for men. A similar picture was seen for the proportion of participants that had smoked 10 pack years or more which was much lower in Tartu for women than in Reykjavik and Uppsala, respectively (13.2% vs. 33.7 and 29.2%, p < 0.001). (Fig. 1). Of the participants with CAO the majority (57-67%) did not have a previous diagnosis of asthma or COPD. ALTANA Aventis AstraZeneca Boehringer-Ingelheim Chiesi GlaxoSmithKline Merck Novartis Pfizer Schering-Plough Sepracor University of Kentucky Landspitali-University Science Fund Astra Zeneca in Iceland GlaxoSmithKline in Iceland Swedish Heart-Lung Foundation Swedish Heart and Lung Association GlaxoSmithKline, Sweden Astra Zeneca |
---|